This webinar will overview the potential for liquid biopsy approaches to monitor therapy resistance in lung cancer.
Lung adenocarcinoma is the most prevalent subtype of lung cancer and characterized by considerable morphological and mutational heterogeneity, which is the primary source of therapy resistance and tumor progression. For many targeted treatments, the underlying molecular alterations leading to therapy resistance are well established. However, frequent tissue sampling to verify such alterations and adapt treatment strategies is not possible. Liquid biopsy approaches are potentially appropriate to overcome these obstacles: Circulating tumor DNA might be superior to tissue biopsies in representing tumor heterogeneity. In addition, frequent blood draws are feasible to monitor molecular alterations even in research subjects who suffer from substantial comorbidities.
In this webinar, Dr. Holger Sültmann of the German Cancer Research Center will discuss liquid biopsy approaches to monitor lung cancer progression using tumor markers in the blood. The focus will be on nucleic acid mutation detection and quantification in clinical samples and their relevance for diagnostics.
The webinar will also address strengths and limitations of PCR- and NGS-based analysis technologies.